title: Ranibizumab for High-Risk Proliferative Diabetic Retinopathy: An Exploratory Randomized Controlled Trial.
abstract: OBJECTIVE
  To compare the efficacy and safety of intravitreal ranibizumab (IVR) in monotherapy or associated with panretinal photocoagulation (PRP) versus conventional PRP, for high-risk proliferative diabetic retinopathy (PDR) without vitreoretinal traction.
  
  
  METHODS
  Multicenter randomized trial, with 3 treatment arms: PRP versus IVR alone and PRP + IVR combined treatment. Follow-up was performed at months 3, 6 and 12.
  
  
  RESULTS
  Thirty-five subjects were randomized and 32 used for analysis. Complete regression of neovessels elsewhere occurred in 100% (PRP + IVR), 75% (IVR) and 69.2% (PRP) and for neovessels of the disk in 44.4% (PRP + IVR), 37.5% (IVR) and 30.8% (PRP). During the 1-year duration of treatment, there was no need for laser rescue treatment in IVR-treated eyes.
  
  
  CONCLUSIONS
  This trial suggests that the use of IVR is safe and may have a beneficial effect in the treatment of eyes with high-risk PDR.
  
  
  CONCLUSIONS
  Ranibizumab appears to have a place in the treatment of PDR.
authors.affiliation: AIBILI, Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal.
authors.forename: João
authors.initials: J
authors.lastname: Figueira
authors.forename: Rufino
authors.initials: R
authors.lastname: Silva
authors.forename: José
authors.initials: J
authors.lastname: Henriques
authors.forename: Paulo
authors.initials: P
authors.lastname: Caldeira Rosa
authors.forename: Inês
authors.initials: I
authors.lastname: Laíns
authors.forename: Pedro
authors.initials: P
authors.lastname: Melo
authors.forename: Sandrina
authors.initials: S
authors.lastname: Gonçalves Nunes
authors.forename: José
authors.initials: J
authors.lastname: Cunha-Vaz
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation; D053844:Lasers, Solid-State / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000627:therapeutic use*; D019233:Retreatment; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab